| Literature DB >> 35633940 |
Yang Liu1,2, Gong-Ming Gao1, Kai-Yuan Yang1, Lu-Ming Nong1.
Abstract
Intervertebral disc (IVD) degeneration, which is common among elderly individuals, mainly manifests as low back pain and is caused by structural deterioration of the nucleus pulposus (NP) due to physiological mechanical stress. NP mesenchymal stem cells (NPMSCs) around the IVD endplate have multidirectional differentiation potential and can be used for tissue repair. To define favorable conditions for NPMSC proliferation and differentiation into chondroid cells for NP repair, the present study simulated periodic mechanical stress (PMS) of the NP under physiological conditions using MSC chondrogenic differentiation medium and recombinant human BMP-2 (rhBMP-2). rhBMP-2 effectively promoted NPMSC proliferation and differentiation. To clarify the mechanism of action of rhBMP-2, integrin alpha 1 (ITG A1) and BMP-2 were inhibited. PMS regulated the BMP-2/Smad1/RUNX2 pathway through ITG A1 and promoted NPMSC proliferation and differentiation. During tissue-engineered NP construction, PMS can effectively reduce osteogenic differentiation and promote extracellular matrix protein synthesis to enhance structural NP recovery.Entities:
Keywords: Cell biology; Stem cells research; Tissue engineering
Year: 2022 PMID: 35633940 PMCID: PMC9136668 DOI: 10.1016/j.isci.2022.104405
Source DB: PubMed Journal: iScience ISSN: 2589-0042
Figure 1Stem cell identification and proliferation and differentiation tests
(A) Cell morphology under a light microscope. Magnification: 40×. Scale bar: 50 μm.
(B) Cell surface markers (CD90, CD105, CD73, CD34, CD45, and HLA-DR) of NPMSCs were detected by flow cytometry.
(C) The cell proliferation rate was measured by CCK-8 assay. The number of cells gradually increased and was significantly higher on day 5 than on days 3 and 1. The value-added rate (CCK-8 signal ratio) was used to assess the number of cells. The value-added rate reached a peak on day 5 and was slightly decreased on day 7; however, the rate remained significantly higher than that on days 1 and 3. Results are presented as the mean ± SD of three independent experiments (∗p<0.05).
(D) Levels of COL 2A1 and ACAN mRNA expression under the normal and MCDM culture conditions were detected by quantitative RT–PCR. Under the MCDM conditions, the levels of COL 2A1 and ACAN mRNA expression were effectively increased. Results are presented as the mean ± SD of three independent experiments (∗∗p<0.01).
(E–G) The protein levels of COL 2A1 and ACAN were analyzed by western blotting (E), and the relative quantitative data (F, G) were calculated. GAPDH was used as an internal control. Results are presented as the mean ± SD of three independent experiments (∗p < 0.05).
Figure 2PMS effectively promoted the proliferation and differentiation of NPMSCs
(A) The CCK-8 assay results showed that the rate of proliferation was significantly higher in the PMS group than in the MCDM group on days 5 and 7, and the rate of proliferation was significantly increased when MCDM was combined with PMS. Results are presented as the mean ± SD of three independent experiments (∗p < 0.05, ∗∗∗p < 0.001).
(B) The levels of COL 2A1 and ACAN mRNA expression in the MCDM, PMS, and MCDM + PMS groups were detected by quantitative RT–PCR. The results showed that the mRNA expression of COL 2A1 and ACAN was significantly increased in the MCDM + PMS group compared with that in two other groups. Results are presented as the mean ± SD of three independent experiments (∗p < 0.05, ∗∗p < 0.01). (A–B) MCDM was used as an internal control.
(C–F) The protein levels of COL 2A1, ACAN, and BMP-2 were analyzed by western blotting (C), and the relative quantitative data (D–F) were calculated. GAPDH was used as an internal control. Results are presented as the mean ± SD of three independent experiments (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
Figure 3BMP-2 stimulated the proliferation and differentiation of NPMSCs
(A–C) The protein levels of COL 2A1 and ACAN were assayed by western blotting (A), and the relative quantitative data (B and C) were calculated. GAPDH was used as an internal control. The results showed that the protein expression of COL 2A1 and ACAN at 200 ng/mL rhBMP-2 was higher than that in the other groups. Results are presented as the mean ± SD of three independent experiments (∗p < 0.05, ∗∗∗p < 0.001).
(D and E) BMP-2 was knocked down using a silencing agent. The reagent effectively reduced the expression of BMP-2 protein in the cells. Results are presented as the mean ± SD of three independent experiments (∗∗∗p < 0.001).
(F–H) The protein expression of COL 2A1 and ACAN was significantly decreased after BMP-2 knockdown under PMS. Results are presented as the mean ± SD of three independent experiments (∗∗∗p < 0.001).
(I–J) Representative images of immunofluorescence staining for BMP-2 were obtained; and the relative fluorescence intensity in each group was calculated. Results are presented as the mean ± SD of three independent experiments (∗∗∗p < 0.001).
Figure 4Construction of tissue-engineered NP by NPMSCs and the chitosan composite fibrin gel scaffold
(A) Representative images of the fibrin gel scaffolds at various concentrations were acquired by electron microscopy.
(B) Representative electron micrographs of tissue-engineered NP constructed by NPMSCs and the chitosan composite fibrin gel scaffold. The growth of NPMSCs was better than that in the other groups when the concentration of the chitosan composite fibrin gel scaffold was 50 mg/mL. The white arrows indicate cells attached to the scaffold.
(C) Representative histological images of tissue-engineered NP were obtained. Alone used BMP-2 can promote the differentiation of cartilage-like cells, also cause its osteogenic differentiation. Under the combined action of PMS, osteogenic differentiation was obviously inhibited. Magnification: 40× (left), 200 × (right). Scale bars: 50 and 20 μm for low and high magnification, respectively. Determination of sustained release performance of scaffolds see also Figure S2.
Figure 5PMS promoted the proliferation and differentiation of NPMSCs through activation of the BMP-2/Smad1/Runx2 axis by ITG A1
(A–H) The protein levels of Smad1, RUNX2, ITG A1, BMP-2, COL 2A1, and ACAN were analyzed by western blotting (A, C, E, G), and the relative quantitative data (B, D, F, H) were calculated. GAPDH was used as an internal control. (A–B) BMP-2 + PMS effectively promoted the expression of SMAD1 and Runx2. Results are presented as the mean ± SD of three independent experiments (∗p < 0.05). (C–D) The knockdown reagent effectively reduced the expression of ITG A1. Results are presented as the mean ± SD of three independent experiments (∗∗∗p < 0.001). (E–F) The expression of all proteins was decreased when ITG A1 was knocked down. Results are presented as the mean ± SD of three independent experiments (∗∗∗p < 0.001). (G–H) The protein expression of ITG A1 was not influenced by the knockdown of BMP-2, and the expression of other proteins was decreased. Results are presented as the mean ± SD of three independent experiments (∗p < 0.05, ∗∗∗p < 0.001).
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| APC anti-human CD34 Antibody | BioLegend | Cat#343510; RRID: |
| PE anti-human CD45 Antibody | BioLegend | Cat#368510; RRID: |
| FITC anti-human CD73 (Ecto-5′-nucleotidase) Antibody | BioLegend | Cat#344016; RRID: |
| FITC anti-human CD90 (Thy1) Antibody | BioLegend | Cat#328108; RRID: |
| PE anti-human CD105 Antibody | BioLegend | Cat#323206; RRID: |
| APC anti-human HLA-DR Antibody | BioLegend | Cat#307610; RRID: |
| FITC Human IgG1 Isotype Control Recombinant Antibody | BioLegend | Cat#403508; RRID: |
| APC Human IgG1 Isotype Control Recombinant Antibody | BioLegend | Cat#403506 |
| PE Human IgG1 Isotype Control Recombinant Antibody | BioLegend | Cat#403504 |
| Anti-Integrin alpha 1 antibody | Abcam | Cat#ab200570 |
| Recombinant Anti-BMP2 antibody [EPR20807] | Abcam | Cat#ab214821; RRID: |
| Anti-Smad1 antibody[EPR5522] | Abcam | Cat#ab126761; RRID: |
| Anti-RUNX2 antibody | Abcam | Cat#ab23981; RRID: |
| Anti-Collagen II antibody | Abcam | Cat#ab34712; RRID: |
| Anti-Aggrecan antibody[6-B-4] | Abcam | Cat#ab3778; RRID: |
| Anti-GAPDH antibody[6C5] - Loading Control | Abcam | Cat#ab8245; RRID: |
| Goat Anti-Rabbit IgG H&L (HRP) antibody | Abcam | Cat#ab205718; RRID: |
| Goat Anti-Mouse IgG H&L (HRP) antibody | Abcam | Cat#ab205719; RRID: |
| Chitosan | Sigma-Aldrich | Cat#1105508 |
| Sodium tripolyphosphate | Sigma-Aldrich | Cat#238503 |
| Genipin | Sigma-Aldrich | Cat#G4796 |
| TWEEN ® 80 | Aladdin | Cat#T118633 |
| Span™ 80 | aladdin | Cat#S110840 |
| Petroleum ether | aladdin | Cat#P119716 |
| Paraffin liquid | aladdin | Cat#P104805 |
| Human BMP-2 Recombinant Protein | Gibco | Cat#PHC7141 |
| DAPI solution | Thermo Scientific | Cat#62248 |
| Fibrinogen from human plasma | Sigma-Aldrich | Cat#F3879 |
| Thrombin from human plasma | Sigma-Aldrich | Cat#T7009 |
| BMP-2 siRNA (h) | Santa Cruz | Cat#sc-39738 |
| Integrin α1/ITGA1/CD49a siRNA (h) | Santa Cruz | Cat#sc-43125 |
| TRIzol Reagent | Invitrogen | Cat#15596018 |
| RevertAid First Strand cDNA Synthesis Kit | Thermo Scientific | Cat#K1622 |
| SYBR™ Green PCR Master Mix | Applied Biosystems | Cat#4309155 |
| BMP-2 Human ELISA Kit | Invitrogen | Cat#EHBMP2 |
| Cell Counting Kit-8 | Dojindo Molecular Technologies | Cat#CK04 |
| SuperSignal™ West Femto Maximum Sensitivity Substrate | Thermo Scientific | Cat#34095 |
| Pierce BCA Protein Assay Kit | Thermo Scientific | Cat#23225 |
| RIPA Lysis and Extraction Buffer | Thermo Scientific | Cat#89901 |
| PMSF Protease Inhibitor | Thermo Scientific | Cat#36978 |
| Primary cultures of nucleus pulposus mesenchymal stem cells(NPMSCs) | This study | N/A |
| This study | N/A | |
| ACAN forward GATCCTTACCGTAAAGCCCATC | This study | N/A |
| ACAN reverse CTCCAGTCTCATTCTCAACCTC | This study | N/A |
| COL 2A1 forward CAAGAACAGCATTGCCTATCTG | This study | N/A |
| COL 2A1 reverse GATAACAGTCTTGCCCCACTTA | This study | N/A |
| Human GAPDH Endogenous Reference Genes Primers, 10 μM | Sangon Biotech | Cat#B661104-0001 |
| FlowJo_v10.6.2 | FlowJo | |
| Prism 9 | GraphPad | |
| ImageJ_v1.8.0 | ImageJ | |
| DMEM-12 (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12) | Gibco | Cat#11320033 |
| Fetal Bovine Serum | Gibco | Cat#12664025 |
| Goat Serum, New Zealand Source | Gibco | Cat#16210064 |
| Mesenchymal Stem Cell Chondrogenic Differentiation Medium | ScienCell | Cat#7551 |
| Penicillin-Streptomycin solution | Gibco | Cat#15140122 |
| 0.25% Trypsin-EDTA | Gibco | Cat#25200072 |
| Type II Collagenase | Gibco | Cat#17101015 |